Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Receivables - Other: 2022-2024

Historic Receivables - Other for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $2.6 million.

  • Taysha Gene Therapies' Receivables - Other changed negligibly% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.6 million for FY2024, which is negligibly% changed negligibly from last year.
  • Per Taysha Gene Therapies' latest filing, its Receivables - Other stood at $2.6 million for FY2024, which was down 0.00% from $2.6 million recorded in FY2023.
  • Over the past 5 years, Taysha Gene Therapies' Receivables - Other peaked at $2.6 million during FY2022, and registered a low of $2.6 million during FY2022.
  • Its 3-year average for Receivables - Other is $2.6 million, with a median of $2.6 million in 2024.